ICH Good Clinical Practice (GCP) for Certified Clinical Research Coordinator (CCRC) Practice Exam

These questions are part of the practice quiz. Start practicing

• What do you call a clinical trial conducted according to a single protocol but at more than one site?
• What term refers to detailed, written instructions to achieve uniformity of the performance of a specific function?
• What should be done about deviations from the protocol?
• To document informed consent, which documents are described as used?
• Who should the sponsor designate to advise on trial-related medical questions or problems?
• What does statistically controlled sampling in monitoring pertain to?
• Who is responsible for the medical care and medical decisions for trial subjects?
• Which statement best describes the primary variable in a clinical trial?
• Which item is NOT a data element for expedited reports?
• Which term identifies the formal approval by the IRB to conduct the trial at the site?
• Where should the financial aspects of the trial be documented?
• Which statement best describes an audit in clinical trials?
• Which term represents all information in original records and certified copies necessary for reconstruction and evaluation of the trial?
• Which body must approve the inclusion of subjects for whom consent may be provided by a legally acceptable representative in non-therapeutic trials?
• Which term refers to the original documents, data, and records used during a clinical trial?
• Which element describes the trial's design and includes a schematic diagram of its design, procedures, and stages?
• Which statement is true about voluntary participation and withdrawal?
• Regarding randomization and unblinding, which statement is correct?
• Which term is used to describe a method where a participant or investigator is unaware of the treatment assignment?
• Individuals whose willingness to volunteer in a clinical trial may be unduly influenced by expectation, benefits associated with participation, or hierarchical retaliation are referred to as what?
• Which item should the sponsor obtain from the IRB/IEC to confirm GCP compliance?
• Which statement about auditors is correct?
• What must be maintained for the randomization process and potential code-breaking?
• What document provides detailed, written instructions to achieve uniformity of performance of a specific function?
• What should be signed to confirm agreement to the protocol?
• Which term refers to a study conducted across more than one site to improve generalizability?
• Which action ensures data can be recovered in case of system failure?
• If a single primary variable cannot be selected from multiple measurements, what strategy is recommended?
• Equivalence and non-inferiority trials are divided into two major objective-based categories according to their goals. Which pair describes these categories?
• Clinical trials should be conducted in accordance with ethical principles originating from which source?
• The plan outlining what aspects of a trial are to be evaluated is described by which topic?
• Before initiating a clinical trial, how should foreseeable risks and inconveniences be weighed in relation to anticipated benefits for the subject and society?
• Phase II primary objective?
• Which document is used to document the agreement between the investigator and sponsor to the protocol/amendments and the CRF?
• When may the investigator implement a deviation without prior IRB/IEC approval?
• Which statement describes ensuring information for trial personnel about protocol and investigational products?
• SUSARs require expedited reporting to regulatory authorities within what general timeframe?
• Phase III primary objective?
• Which document provides instructions for handling of investigational products and trial-related materials?
• What follow-up is advised for subjects who withdraw from treatment?
• Which document covers the decoding procedures for blinded trials?
• The set of data elements (patient initials, suspected medicinal product, other treatments, details of the suspected ADR, details on the reporter, and administrative details) are used for expedited reports to ensure what?
• One of the objectives of the ICH E8 document is to present an overview of the ICH clinical safety and efficacy documents and facilitate access to guidance pertinent to clinical trials. Which option best captures this objective?
• Which term is a declaration of confirmation by the auditor that an audit has taken place?
• Dose-response relationships can be evaluated in which phases of development?
• Who is the person primarily responsible for the proper conduct of the trial at the site?
• According to GCP guidance, who should the sponsor utilize to supervise the overall conduct of the trial, handle statistics, verify data, conduct statistical analysis, and prepare trial reports?
• Which items should the sponsor obtain to confirm IRB/IEC review and operation?
• What does the IRB/IEC determine as appropriate for continuing review?
• What must a monitoring report include after each site visit?
• Annual progress report to whom?
• Which topic focuses on the methods for statistical evaluation in a trial?
• 4.5.4 describes what about deviations to eliminate immediate hazards?
• Which member of the trial team is designated and supervised by the investigator at the trial site to perform critical trial-related procedures and/or to make important trial-related decisions?
• What entity is responsible for deciding whether a reaction in a trial using an active comparator or placebo should be reported to the manufacturer or to regulatory agencies?
• Which term is a person or an organization (commercial, academic, or other) contracted by the sponsor to perform one or more of a sponsor's trial-related duties and functions?
• Under what guideline condition may abbreviated study reports be acceptable?
• Which statement about formulation details is correct?
• Which statement best characterizes the design techniques to avoid bias in clinical trials?
• Under what condition is it recommended to inform the subject's primary physician about participation?
• Which groups are explicitly included under Special Populations in Phase IV guidelines?
• Which option lists the acceptable locations for documenting shipping records for investigational products?
• Which of the following is required for an independent data-monitoring committee (IDMC) to effectively operate?
• Which statement describes how monitors should handle standard operating procedures?
• Which factor is essential when selecting auditors?
• Which element defines how safety data are collected and reported?
• What approach should be implemented to assure the quality of every aspect of the trial?
• Which statement best describes the focus of the Development Plan Considerations?
• In Phase I, what is the primary objective?
• Which statement reflects a data security requirement for electronic data handling?
• Which statement best describes medications permitted before and/or during the trial?
• The Development Plan considerations address which of the following aspects?
• Which statement is true about familiarization with the investigational product use?
• Before informed consent may be obtained, what should the investigator provide?
• Which topic involves evaluating the safety and tolerability of a therapy in a clinical trial?
• During and after participation, what is the investigator's obligation regarding adverse events and significant laboratory values?
• Which statement best describes the efficacy assessment in a clinical trial?
• What must the sponsor verify regarding a subject's consent for direct access to original medical records?
• What should be documented regarding the responsibilities of coordinating and participating investigators before starting the trial?
• Which document identifies the IRB/IEC approval (dated and documented) of trial related documents?
• Phase III typically includes further exploring which aspect in a broader population?
• Which statement about source data verification is correct?
• In the Phase IV design, what aspect relates directly to safety monitoring?
• Which statement best reflects the expected time frame for conducting and completing the trial?
• Which statement best defines an Adverse Event (AE) in a clinical trial?
• The extent and nature of monitoring should be based on considerations such as objective, purpose, design, complexity, blinding, size, and endpoints. True or False?
• Which statement about Multiple Primary Variables is true?
• Which term is defined as a printed, optical, or electronic document designed to record all protocol-required information to be reported to the sponsor on each trial subject?
• Who bears responsibility for implementing and maintaining quality assurance and quality control systems in a trial?
• What does the term Investigator-Adequate Resources imply?
• The method and manner of compensation to trial subjects should...
• Which scenario would be categorized as an 'Other Observations' item?
• Which document describes how, in an emergency, the identity of blinded investigational product can be revealed without unblinding remaining subjects?
• What best describes the investigator's obligation to IRB/IEC communication?
• Which term describes the ongoing evaluation of trial progress and subject safety by a monitor, and the reporting of findings to the sponsor?
• All investigators must conduct the trial in strict compliance with which directive?
• Which of the following best describes the Therapeutic Confirmatory objectives?
• Which term describes documents that permit evaluation of the conduct of a study and the quality of the data produced?
• What must be included in informing the subject about the trial?
• Which term describes a procedure in which one or more parties to the trial are kept unaware of the treatment assignment?
• An adverse reaction, the nature or severity of which is not consistent with the applicable product information, is known as what?
• If prior consent of the trial subject or the subject's legally acceptable representative is not possible, what must the IRB/IEC determine?
• What should the sponsor provide when regulatory requirements require coverage for trial-related injuries?
• Which topic focuses on presenting data and identifying the subjects to be evaluated?
• In GCP, how are efficacy data distinguished from safety data?
• What is required when transferring any trial-related duty to a CRO?
• Nonclinical studies focus on which areas to support initial human dose?
• Which topic encompasses trial monitoring and interim analyses?
• Which statement correctly describes expedited review for minor changes?
• Which is NOT a standard toxicology heading under nonclinical studies?
• Before entering an agreement with an investigator, what should the sponsor provide?
• Accrual rate refers to which aspect of a trial?
• What term describes a unique identifier assigned by the investigator to each trial subject to protect the subject's identity and used in lieu of the subject's name?
• Who should be informed of storage determinations?
• Phase IV objectives may include which of the following?
• During the trial, to whom should the investigator provide documents subject to review?
• What must be included in the justification for sample size?
• Non-therapeutic trials conducted with consent of a legally acceptable representative should be conducted under which condition?
• Which document is listed as being located at both the investigator/institution and sponsor locations to reflect agreement on protocol/amendments and CRF?
• What should be included in written information for payment?
• Which document demonstrates competence of the facility to perform required tests and support reliability of results?
• Early nonclinical safety studies should provide information to support which item related to first‑in‑human testing?
• Which description best matches an Impartial Witness in clinical trials?
• In emergency enrollment where prior consent is not possible, which statement is NOT correct?
• Which statement accurately describes the staffing and facilities requirement?
• What is required regarding follow-up information for expedited ADR reports?
• Under what circumstance may the IRB/IEC require that more information be given to subjects beyond standard guidance?
• What is the primary purpose of the coding in blinded trials?
• The sponsor's system for the disposition of unused IP should ensure what?
• Which parties are responsible for maintaining documentation of regulatory authorities' authorization/approvals/notifications for protocol amendments and other documents?
• Which statement is not described as part of the Investigator's Brochure's purpose?
• What is the recommended approach when presenting conclusions about efficacy in the summary?
• If the sponsor terminates or suspends a trial, what is the investigator's obligation?
• What must be provided to the IRB/IEC to obtain its favorable opinion?
• What should be done with the observations and findings of auditors?
• Which statement best describes pre-trial regulatory notification?
• The location(s) where trial-related activities are actually conducted are referred to as what?
• Which type of trial is designed to provide firm evidence of efficacy or safety?
• What should the investigator do for any deviation from approved protocol?
• Which item is NOT typically considered a key data element for expedited reports of serious adverse reactions?
• Which is a written description of a change to or formal clarification of a protocol?
• The CRO should implement which of the following quality processes?
• How should study reports be prepared in relation to guidelines?
• Surrogate variables are used as reliable predictors of clinical benefit in various indications. Which option matches this idea?
• The design of case report forms (CRFs) in multicenter trials should capture what?
• The document that presents the results and interpretations of a clinical trial is called what?
• Which ICH guideline covers the structure and content of clinical study reports?
• Which term refers to original documents, data, and records?
• Phase III is intended to provide an adequate basis for what?
• In selecting a control group, which statement best describes acceptable comparisons?
• What is the requirement regarding those who assist with the trial?
• Which statement best describes what is involved in establishing the IRB/IEC's formal basis?
• Which term is used for an ADR that is not described in the product labeling or Investigator's Brochure?
• Which statement best describes how missing, unused, and spurious data should be handled in a GCP trial?
• Which statement about exploratory trials is true?
• What should the summary of efficacy data include to support conclusions about a treatment's effect?
• If monitoring or auditing identifies serious and persistent noncompliance, what should the sponsor do?
• Regarding structural similarities to other known compounds, which statement is appropriate?
• Where should the finalized CRFs be kept after completion and which copy is retained by the sponsor?
• Which statement combines the enrollment number and power calculations to justify the trial size?
• What should be described about the population to be studied?
• Which statement best describes how information in the Investigator's Brochure should be presented?
• If a subject withdraws prematurely, what should the investigator do regarding the reasons?
• Progress Report: How often should the investigator submit written summaries of trial status to the IRB/IEC?
• What is the key purpose of summarizing the clinical database in the report?
• Which option best describes the Introduction's comprehensive content regarding the product?
• Which term refers to the operational techniques and activities undertaken within the quality assurance system to verify that requirements for quality of trial-related activities have been fulfilled?
• Which description best characterizes study endpoints?
• Which adverse drug reactions (ADRs) require expedited reporting to all concerned investigators/institutions, IRBs/IEC(s) where required, and regulatory authorities?
• Post-study adverse events are typically reported by the investigator to the sponsor. true or false?
• Prior to initiating a trial, what should be defined, established, and allocated?
• Source Documents: What is the purpose of source documents in a clinical trial?
• Which role is an individual who both initiates and conducts a trial and under whose immediate direction the investigational product is administered to a subject?
• Which term describes all noxious and unintended responses to a medicinal product related to any dose?
• Which option best describes what the introduction to nonclinical pharmacology should include?
• Which term refers to any investigation in human subjects intended to discover or verify the clinical, pharmacological and/or other pharmacodynamic effects of an investigational product, and/or to identify adverse reactions, and/or to study absorption, distribution, metabolism, and excretion of an investigational product with the object of ascertaining its safety and/or efficacy?
• Which element describes the route of administration, dosage, dosage regimen, and treatment periods?
• When any trial-related duties are transferred to a CRO, what must be specified in writing?
• When should the written informed consent form and any other written information be revised, and what approval is required before use?
• Which term refers to the written evaluation provided by the sponsor's auditor summarizing the audit results?
• What documentation identifies the IRB/IEC review and approval and notes the version number and date of documents?
• Which statement best describes the sponsor's responsibilities for the investigational product?
• Which items should be included in the investigational product accountability records?
• Which topic specifically covers issues arising when therapy is blinded during a trial?
• Which term refers to adherence to trial-related requirements and Good Clinical Practice (GCP) requirements?
• During trial reviews, special attention should be paid to trials that may include...
• In nonclinical pharmacokinetics, which aspect is specifically addressed?
• Which trial type is an adequately controlled study in which hypotheses are stated in advance and evaluated to provide firm evidence of efficacy or safety?
• Which statement best describes subject exclusion criteria?
• Data transformation is typically used to?
• Which item best demonstrates IRB/IEC compliance with GCP and applicable laws?
• Where are analysis sets defined in a protocol?
• Which activities are included in the IRB/IEC's responsibilities related to meetings?
• Which of the following is an objective of the ICH safety guidance?
• Which statement best reflects the Marketing Experience section?
• Upon completion of the trial, what should the investigator do?
• Which statement best describes the 'Considerations for Individual Clinical Trials' category?
• The investigator should be thoroughly familiar with the appropriate use of the investigational products as described in which sources?
• Which statement accurately describes language in the informed consent process regarding waiving legal rights?
• Before starting a trial, which element is most appropriate to be clearly specified in the protocol?
• Who should provide Curriculum Vitae and other documents evidencing qualifications of investigators and sub-investigators?
• What does SUSAR stand for?
• A Therapeutic Confirmatory study primarily aims to do which?
• Which document describes the written description of a change to the protocol?
• If a subject cannot read, what is required during the consent discussion?
• Before initiating a trial, which approvals must the investigator obtain from the IRB/IEC?
• Which information must be specified about treatments for each trial group?
• What must be documented regarding data changes to electronic systems?
• Which topic covers the set of subjects to be evaluated and the presentation of data?
• Which statement best describes sponsor's audit purpose?
• What should the Summary emphasize?
• Which statement accurately describes the use of documentation for all subjects who began trial procedures?
• For a fatal or life-threatening ADR, the initial notification must include which of the following elements?
• Which document records the identity, purity, and strength of investigational products to be used in the trial?
• Should changes in inclusion and exclusion criteria remain constant during recruitment?
• Where is the timing of any planned interim analysis described?
• Which term is defined as a standard for the design, conduct, performance, monitoring, auditing, recording, analyses, and reporting of clinical trials that provides assurance that the data and reported results are credible and accurate, and that the rights, integrity, and confidentiality of trial subjects are protected?
• Why is blinded therapy case management included in expedited reporting guidelines?
• Written procedures for handling the investigational product should include which of the following?
• Interim analysis and early stopping are used to compare treatment arms with respect to what?
• Considerations for the Development Plan emphasize which aspect?
• Which statement describes monitoring guidance for procedures?
• Phase II typically starts with initiation of studies in which population?
• Who should retain records of the changes and corrections to CRFs?
• IRB/IEC should obtain information about payments to and compensation available to subjects.
• Before starting the trial, how should regulatory submissions be dated?
• What distinguishes an Adverse Drug Reaction (ADR) from a general Adverse Event (AE)?
• Phase IV studies may involve which of the following activities?
• Interim or annual reports are provided to which parties?
• Which documents guide the trial design, protocol, and conduct?
• In blinded trials, what should the coding system include?
• In superiority trials, which approach most convincingly demonstrates efficacy?
• The sponsor's procedures should include actions for unused investigational product. Which action is correct?
• Which term describes a sponsor-organized group that coordinates the conduct of a multicenter trial?
• In a Human Pharmacology study, which objective is typically included?
• If the investigator terminates or suspends a trial without prior agreement of the sponsor, what is required?
• What documentation certifies the identity, purity, and strength of investigational products to be used in the trial?
• Which activity is a monitor's responsibility to ensure the trial is conducted and documented properly?
• Which item should be included to provide background by referencing literature and data?
• Which topic is dedicated to the act of reporting study results?
• What documentation records agreements or significant discussions regarding trial administration, protocol violations, trial conduct, adverse event (AD) reporting?
• What does blinding accomplish in a trial?
• What is required regarding the immediate SAE report?
• Investigational products should be manufactured, handled, and stored in accordance with which standard?
• Which statement best describes IRB/IEC record retention duration?
• Which statement about the Independent Data Monitoring Committee (IDMC) is true?
• Which topic addresses the integrity of data and the validity of computer software used in data handling?
• Adverse events reporting timeframe?
• What form should the Investigator's Brochure information take?
• Essential Documents are those that demonstrate compliance with which standards?
• The term used for the physical and mental well-being of the trial subjects is what?
• In a clinical trial, which entity takes responsibility for initiation, management, and financing of the trial?
• Which statement best describes the purpose of subject inclusion criteria in a clinical trial?
• Data transformation in analysis is used to do what?
• Which element should include the power considerations when determining sample size?
• Which document would you reference to verify the IRB/IEC approval status and its date/version information?
• The sponsor and the investigator/institution should sign the protocol, or an alternative document, to confirm agreement. What action confirms agreement?
• Which document records the method for randomization of the trial population?
• Which item is an example of 'Other Observations' in expedited reporting?
• What is the purpose of the Subject Identification Code List?
• What information should be provided for the clinical laboratories and other medical or technical departments involved in the trial?
• Which design approaches testing two or more treatments by using different combinations and evaluating potential interactions?
• Which topic describes the procedural aspect of submitting expedited ADR reports?
• Which element should be included regarding patients who stop treatment prematurely in Phase IV trials?
• Which document addresses the financial aspects of the trial?
• Why might significance levels be adjusted when multiple analyses are performed?
• What should the investigator maintain regarding significant trial-related duties?
• The investigator should comply with the protocol; what is required?
• What is the primary purpose of a parallel group design?
• In a dose-ranging program, what is the primary objective?
• What term describes the pharmaceutical form of an active ingredient or placebo that is tested or used as a reference in a clinical trial?
• The subtopic 'Evaluation and Reporting' addresses which aspect of trial data?
• When the sponsor discontinues clinical development of an investigational product, who should be notified?
• Which requirement ensures that a trial's conduct aligns with approved procedures?
• Outside consultant(s) may be appointed for what purpose?
• Phase III aims to complete the information needed to support what?
• What is the required documentation for informed consent?
• What is the purpose of documenting retained body fluids/tissue samples?
• Which trial design randomizes participants to two or more arms, each arm receiving a different treatment?
• Who is responsible for investigational product accountability at the trial site(s)?
• What should accompany the communication of new information to the subject to continue participation?
• Exploratory trials should have clear and precise objectives.
• Which statements best describes what is subject to expedited reporting for adverse drug reactions?
• Quality assurance activities require written SOPs. Who is responsible for implementing and maintaining QA/QC systems with written SOPs?
• What are the purposes of trial monitoring?
• What should the analysis plan consider regarding early withdrawals and protocol violations?
• What is the written report from the monitor to the sponsor after each site visit or other trial-related communication called?
• Phase I is most typically which kind of study?
• Which statement describes a composite variable?
• When preparing the clinical study report, what should the summary of the clinical database include?
• Which term describes the set of activities designed to ensure the trial's quality by monitoring compliance and processes, not by data itself?
• What should be addressed in the nonclinical pharmacokinetics section?
• In GCP trials, what level of significance is commonly used for hypothesis testing?
• Before the clinical phase of the trial commences, what should be documented?
• Which concept ensures that trial results are not biased by the method of assigning participants to groups?
• What should the analysis plan address?
• Which topic outlines how variables are chosen and how data are collected?
• Which statement best describes the tone of the Investigator's Brochure?
• Which term is defined as any untoward medical occurrence in a patient or trial subject administered a pharmaceutical product, regardless of causal relation?
• Which term describes signs or diseases temporally associated with the use of a medicinal product?
• Where should essential documents be located?
• Who maintains the confidential Subject Identification Code List?
• The Marketing Experience section should identify which information?
• How should clinical study reports be documented?
• In a multicenter trial, who is primarily responsible for ensuring standardized data collection across sites?
• Which document is used to document the financial agreement between the investigator/institution and the sponsor for the trial?
• Which statement best describes the packaging objective for investigational product(s)?
• Which principle places the rights, safety, and well-being of the trial subjects as the most important considerations, taking precedence over science and society?
• Which term refers to any medical or dental facility where clinical trials are conducted?
• Which of the following is explicitly a Phase IV subcategory?
• When planning trials, what should the sponsor ensure regarding safety and efficacy data?
• Under what circumstances might multiple primary variables be appropriate?
• What is the primary purpose of protection of clinical trial subjects under GCP?
• What is GMP's main aim for IP manufacturing?
• Which statement best describes why trial records are maintained?
• Which statement best describes the role of the investigator regarding monitoring and auditing?
• Which term is an investigational or marketed product, or placebo, used as a reference in a clinical trial?
• What should be described when defining response variables?
• Which aspects should the protocol’s analysis plan cover?
• Regardless of completion, what must be done with clinical trial reports?
• In trial documentation, which element identifies the laboratories and other departments involved?
• The plan for the scope of evaluation in a clinical trial is described by which topic?
• Investigators must permit which activities?
• Which two techniques are described as measures to minimize bias in the trial?
• Which statement best reflects the requirement regarding coercion or undue influence in trial participation?
• Why have multiple analysis sets?
• Global Assessment Variables measure what in a clinical trial?
• What documentation should be provided to sponsor and IRB/IEC if termination occurs without sponsor agreement?
• The plan for which variables are collected and how data are gathered is described by which topic?
• How often should investigators check that each subject is following the instructions for using the investigational product?
• What action ensures compliance with GCP regarding oversight?
• All other serious, unexpected ADRs should be filed within how many calendar days after first knowledge?
• Which document serves as the formal record that a subject has given informed consent and is used as part of trial data?
• What document records revisions to normal values/ranges used for medical, laboratory, or technical procedures included in the protocol?
• Randomization provides a sound statistical basis for the evaluation of treatment effects. Which option best expresses this?
• Which statement best reflects a general principle of ICH GCP regarding subject protection?
• Where are the analysis sets typically defined in a clinical trial protocol?
• In SAE reporting, how should subjects be identified?
• Which statement best reflects a monitor's qualification responsibilities?
• Labeling of investigational product(s) must comply with what?
• How often should the IRB/IEC conduct continuing review of ongoing trials, considering risk level?
• What is the term for a report of intermediate results and their evaluation based on analyses performed during the course of a trial?
• Which term refers to an individual or body authorized to consent on behalf of a prospective subject?
• Which term refers to the laws and regulations addressing the conduct of clinical trials of investigational products?
• What is the purpose of pre-specifying the statistical analysis in a protocol?
• Which statement best describes subject protection focus in ICH GCP general principles?
• Freely given informed consent must be obtained from every subject prior to clinical trial participation. Which option reflects a key aspect of this requirement?
• Medical expertise is applied in which area according to the guideline?
• If a trial is prematurely terminated or suspended, what information should be promptly communicated?
• Which statement about sponsor responsibility is true?
• Which statement best describes sponsor responsibilities related to direct access to source data for monitoring and regulatory inspections?
• What population is typically used for safety analyses in a GCP-compliant trial?
• Which role is designated and supervised by the investigator at the trial site to perform critical trial-related procedures?
• The nonclinical pharmacology section should include which of the following?
• What should the Title Page potentially include according to the guidelines?
• The responsibility for medical care and medical decisions for trial subjects rests with which professional?
• Who submits the final report by the investigator to IRB/IEC and, where applicable, to regulatory authorities?
• Noncompliance with protocol, SOPs, GCP, or regulatory requirements by an investigator or sponsor staff should lead to what action?
• What is the purpose of the subject identification code list?
• The Introduction should provide the general approach to what?
• Who must sign and date the written informed consent prior to participation?
• Which statement best describes the sponsor's duty regarding costs of treatment for trial-related injuries?
• Which document documents chronological enrollment of subjects by trial number?
• Phase IV objectives may include the assessment of which type of parameters?
• What term refers to the act of overseeing the progress of a clinical trial and ensuring it is conducted, recorded, and reported in accordance with the protocol, SOPs, GCP, and regulatory requirements?
• What is the purpose of providing relevant and current scientific information about the investigational product to the investigator?
• Under what circumstances are interim results appropriate to include in the clinical study report?
• True or false: The initial expedited ADR report must identify the patient, the suspect product, the reporting source, and indicate that the event is serious and unexpected with a reasonable suspected causal relationship.
• When do Phase IV studies occur in the drug development lifecycle?
• Which statement best represents a core purpose of the ICH E8 document?
• When selecting subjects for a Phase IV study, which factors should be considered?
• What factors influence the sample size in a clinical trial?
• Data handling and record keeping in a GCP trial should ensure which principle?
• Why must the protocol specify the principal features of the proposed statistical analysis before starting?
• In a trial protocol, which elements must be explicitly defined as the primary and secondary outcomes to be measured?
• Does the protocol specify whether and how replacement of withdrawn subjects may occur?
• Ethical considerations in a clinical trial include which of the following?
• After an SAE is reported immediately, what should follow?
• What is the primary purpose of expedited safety reports in the ICH framework?
• What is required before enrolling any subject in a trial?
• Which item is NOT a required element of IRB/IEC confirmation of review?
• The ethical principles underlying GCP and informed consent trace their origin to which document?
• Which term is a committee that a sponsor may organize to coordinate the conduct of a multicenter trial?
• What must be obtained from every subject prior to clinical trial participation?
• What term describes all information in original records and certified copies necessary for reconstruction and evaluation of the trial?
• Which statement best describes the broad aim of the development plan for a new drug?
• Which concept is primarily supported by documentation that ensures the integrity and accuracy of trial data?
• Who is responsible for submitting the final report by the investigator to IRB/IEC and to regulatory authorities where required?
• During the trial, what should the investigator provide to the IRB/IEC?
• The Full Analysis Set is designed to approximate which principle?
• Who keeps the Subject Identification Code List, a confidential list of names of all subjects allocated to trial numbers and the ability to reveal identity when needed?
• An individual who participates in a clinical trial, either as a recipient of the investigational product or as a control, is called what?
• Before initiating the clinical trial(s), what should the sponsor submit to the appropriate authority(ies)?
• After reporting a fatal or life-threatening ADR within 7 days, by when should a more complete report typically be provided?
• What is the primary purpose of documenting normal values/ranges for medical, laboratory, or technical procedures included in the protocol?
• Which statement about the scope of trials is accurate?
• The investigator should ensure that the investigational product(s) are used only in accordance with what?
• Which term is a written description of a trial/study of any therapeutic, prophylactic, or diagnostic agent conducted in human subjects, in which the clinical and statistical description, presentations, and analyses are fully integrated into a single report?
• Blinding is intended to limit bias arising from knowledge of treatment in which aspects?
• Which statement best distinguishes Quality Control from Quality Assurance in GCP?
• Which item provides the description of the population to be studied in the context of Background Information?
• Which documentation should the IRB/IEC consider to assess the investigator's qualifications for a proposed trial?
• What describes the stopping rules or discontinuation criteria for the trial?
• Which term describes adherence to all the trial-related requirements, Good Clinical Practice (GCP) requirements, and the applicable regulatory requirements?
• If a publication policy is not addressed in a separate agreement, what should be established regarding publication of trial results?
• If a trial-related duty is not transferred to the CRO, who retains that duty?
• Which statement best captures the requirement for investigator qualifications?
• Which statement is a required characteristic of changes or corrections to CRFs?
• Which of the following best describes what the IRB/IEC review should encompass?
• What is required to protect the confidentiality of records that could identify subjects?
• Which statement about the investigational product and protocol is true?
• When a trial is terminated or suspended, which parties should be informed promptly and given reasons?
• Which item ensures that references to literature and data relevant to the trial are included?
• Documentation of regulatory authorities' authorization/approvals/notifications required for protocol amendments and other documents should be kept by which parties?
• Which records are required to document the shipment, receipt, disposition, return, and destruction of the investigational product?
• The monitor's responsibilities include ensuring that the trial is conducted and documented properly by carrying out activities when relevant. This is described in which section?
• Which scenario qualifies as a Serious Adverse Event (SAE)?
• When new safety information becomes available during a trial, who must be informed of this information?
• Fatal or life-threatening unexpected ADRs must be reported to regulatory authorities within what timeframe after first knowledge?
• Which term is a written evaluation by the sponsor's auditor of the results of the audit?
• In multisite trials, what should be specified regarding enrollment?
• To document that compensation to subjects for trial-related injury will be available, which locations are listed for documentation?
• Informed Consent is defined as
• Which statement best describes the handling of changes or corrections to the CRF?
• On request from monitor, auditor, IRB/IEC, or regulatory authority, what should the investigator do?
• Which statement supports sample size justification?
• Which documentation category tracks certification, accreditation, QC, external QA, or other validation of procedures used in the protocol?
• Which term denotes the regulatory framework governing clinical trials of investigational products?
• Which term best describes documents which individually and collectively permit evaluation of the conduct of a study and the quality of the data produced?
• Which are the objectives associated with Therapeutic Exploratory studies?
• In Phase II, what is the primary consideration for dosing and regimen?
• How should the investigational product(s) be stored?
• Which term best describes the process of performing a formal review to ensure compliance with the protocol and SOPs?
• Where should signature sheets be maintained?
• During the clinical conduct of the trial, which category includes all documents required in the initial phase plus the following?
• What actions should the investigator take to ensure correct use of the investigational product(s) by each subject?
• When should IRB/IEC decisions be made?
• True or False: Phase IV studies begin after drug approval.
• Which design is defined as evaluating two or more treatments simultaneously through varying combinations and possible interactions?
• Which design typically involves conducting trials at more than one site to gather diverse data?
• Under Investigator-Adequate Resources, what is emphasized?
• Prior to supplying investigational product to a trial site, what must the sponsor obtain?
• A unique identifier assigned by the investigator to protect subject identity when reporting trial data is called what?
• Which document updates the Investigator's Brochure during the trial?
• What type of subject identification code should the sponsor use?
• Which document confirms the formal written agreement among the involved parties before the study begins?
• Development Methodology in the context of the development plan covers what?
• What is the purpose of maintaining a system for retrieving investigational products and documenting retrieval?
• Which document contains pharmacology, toxicology, and prior human experience data on the investigational product to support human studies?
• To document that there are written agreements among involved parties, which location is used?
• What is the primary purpose of allocating trial-related duties and functions before trial start?
• Which definition best describes a Serious Adverse Event (SAE) in GCP?
• In trial planning, which element must be clearly specified in a protocol before the trial begins?
• Which document records the destruction of unused investigational products?
• What should the Introduction contain?
• What is the primary purpose of QA/QC systems in GCP?
• To monitor adequately, monitors should be thoroughly familiar with which of the following?
• If the IRB/IEC withdraws or suspends approval, what should be done?
• Before starting a trial, which statement about IRB approval is correct?
• Which topic is addressed by procedures for monitoring subject compliance?
• What is the requirement for informing all persons assisting with the trial about the protocol and duties?
• Informing the subject's primary physician about participation is recommended under what condition?
• In a multicenter trial, which term refers to a committee organized by a sponsor to coordinate the conduct of the trial?
• Which description is required to justify the number of subjects enrolled?
• Who is primarily responsible for summarizing safety data in the clinical report?
• What is the primary purpose of the Investigator's Brochure?
• Which statement correctly lists the minimum criteria for regulatory reporting of ADRs?
• Post-study events refer to serious adverse events that occurred after completion of a clinical study. In such cases, who is typically responsible for reporting to the sponsor?
• Which Phase I consideration relates to clearance and potential drug-drug interactions?
• What is the primary aim of trial monitoring?
• Which document shows the IRB/IEC is constituted in accordance with GCP?
• In a trial with more than one presentation or use, how should safety reporting be conducted?
• Which statement best describes the purpose of maintaining randomization codes and code-breaking procedures?
• Which entities should sponsor-specific essential documents be retained for in conformance with regulatory requirements?
• Who may be designated to maintain records of the product's delivery to the trial site, the inventory at the site, the use by each subject, and the return to the sponsor or alternative disposition of unused product(s)?
• In multi-center trials, who is responsible for organization and selection of coordinating investigator(s)?
• Which statement best describes the purpose of Any Other Written Information provided to trial subjects?
• What must be obtained before initiating any protocol deviation?
• Which factors determine the extent and nature of monitoring?
• What ensures that each individual involved in conducting a trial is qualified by education, training, and experience to perform their task?
• A transfer of ownership of trial data should be reported to which entity?
• Which data are typically included under safety data in a clinical trial report?
• Which statement about access to source data should be included in the protocol or written agreement?
• To document the existence of the subject and substantiate integrity of trial data collected; to include original documents related to the trial, to medical treatment, and history of subject
• Which document confirms the IRB/IEC has reviewed and approved the protocol and includes the official date of approval?
• May an IRB/IEC invite nonmembers with expertise for assistance?
• Which document provides the written information given to trial subjects to support informed consent?
• Which statement best describes Quality Assurance in clinical trials?
• How should response variables be defined in the protocol?
• The sponsor should maintain records for which activities related to the investigational product's lifecycle?
• 4.5.1 summarizes which concept?
• Which statement ensures site-level enrollment targets are documented for multisite trials?
• What elements should be included in the Phase IV study design?
• Which document contains the objective, design, methodology, and statistical considerations of a trial?
• Who should vote on trial-related matters?
• Which of the following should the IRB/IEC obtain to verify investigator qualifications?
• During Monitoring Procedures, after each site visit, what must a monitoring report include?
• Which of the following describes the Per Protocol Set's components?
• What presentation is useful for safety and efficacy data across multiple trials by indications or subgroups?
• When a CRO has assumed trial-related duties, to whom do references to the sponsor apply?
• Which entities should the sponsor promptly notify about findings that could affect subject safety, trial conduct, or the continued favorable opinion of the IRB/IEC?
• Which term best describes the formal opinion issued by an Independent Ethics Committee regarding trial ethics and participant safety?
• When a subject withdraws due to safety concerns, which data should be documented?
• Publication policy in GCP should be addressed where if not in a separate agreement?
• In Phase I, which objective may be conducted as a secondary objective?
• Which element describes how long subjects participate and when follow-up occurs, including subsequent trial periods?
• Which term describes the process of assigning trial subjects to treatment or control groups using chance to reduce bias?
• Which section addresses the reporting of reactions associated with active comparator or placebo treatment?
• What should the Investigational Brochure describe regarding risks and monitoring?
• Which term describes documentation that allows reconstruction of the course of events?
• What is true about GMP in relation to investigational product coding and labeling?
• Which topic discusses an integrated summary of trial results?
• Who is permitted to vote on trial-related matters within an IRB/IEC?
• Which statement describes the purpose of keeping essential documents post-trial?
• What is the purpose of assigning unique code numbers to the investigational product(s) and to trial subjects?
• Which statement correctly describes the Full Analysis Set?
• Which design element helps ensure prognostic factors are balanced across treatment groups?
• What should the protocol specify to minimize bias?
• Which statement best describes IRB/IEC responsibilities?
• In multicenter trials, what should be provided when investigators collect additional data beyond the core protocol?
• What primarily determines the sample size of a clinical trial?
• Who is responsible for initiating, managing, and financing a clinical trial?
• If the sponsor discontinues clinical development of an investigational product, how long should sponsor-specific essential documents be retained?
• Which aspect must be described about the investigational product to ensure proper administration and traceability?
• Which criterion justifies early termination of a trial?
• What should the investigator ensure about staffing and facilities for the trial?
• Who should sign off on changes or corrections to CRFs made by sponsor-designated representatives?
• Surrogate variables are used in indications where they are believed to be reliable predictors of clinical benefit. True or false?
• What is the purpose of adjusting significance and confidence levels?
• Which statement best describes the CRO's QA/QC duties?
• In the Effects in Humans: Introduction, which topics may be included when available?
• Which best describes how safety findings should be presented in the final report?
• Blinding aims to limit conscious and unconscious bias in which areas?
• Which document records that trial procedures were reviewed with the investigator and the investigator's trial staff?
• Which information must be provided for the qualified physician or dentist responsible for all trial-site medical decisions if the physician is not the investigator?
• Who may inspect trial records as part of QA and regulatory oversight?
• What is the requirement for retention and archiving of trial records?
• What documentation describes shipment dates, batch numbers, and method of shipment for investigational products to enable tracking and accountability?
• What recruitment capability must the investigator demonstrate for the trial?
• What determinations should the sponsor make for the investigational product regarding storage?
• Trials to Show Equivalence or Non-inferiority are divided into two major objective-based categories. What are these two categories?
• Which of the following describes recommended characteristics of an IRB/IEC?
• Which topic covers subgroups, interactions, and covariates?
• What is required when protocol deviations occur?
• What is a primary purpose of packaging for the investigational product?
• Which topic is specifically addressed under pharmacokinetic studies?
• Which statement best describes how an IRB/IEC should operate?
• What describes the procedures for tracking the investigational products, including placebos and comparators?
• Upon completion, what should be provided to the IRB/IEC?
• Which section should include the description of the population to be studied?
• Which documents should the IRB/IEC obtain from the investigator?
• What term describes the act by a regulatory authority of conducting an official review of documents, facilities, records, and related resources for the trial?
• Which item should be described to ensure proper handling, labeling, and traceability of the investigational product during the trial?
• Which category requires reporting within 15 calendar days after first knowledge?
• What is a monitor's duty regarding CRF entries and source documents?
• Before trial initiation, which body’s approval or favorable opinion is required for the protocol?
• Data capture and processing in a trial can transfer data from the investigator to the sponsor through which media?
• Which document records the normal values and ranges for tests used in the protocol?
• In electronic trial data handling, which statement reflects a requirement to protect data integrity?
• Which statement best describes the focus of the Therapeutic Use category?
• What does Direct Access refer to in the context of clinical trials?
• What is required to ensure timely delivery of the investigational product to investigators?
• Which item must be included in the informed consent discussion and form? 4.8.9 content about risks and benefits etc.
• Which records document the qualifications of investigators and sub-investigators?
• If deviations from the original statistical plan occur, what is required for documentation?
• Which document is used to document signatures and initials of all persons authorized to make entries and/or corrections on case report forms?
• Who must notify the sponsor of serious adverse events and related reports?
• Which statement best describes how all clinical trial information should be treated?
• Which term describes a systematic and independent examination of trial related activities and documents to determine whether they were conducted and the data were recorded, analyzed and accurately reported according to the protocol, sponsor's SOPs, GCP, and applicable regulatory requirements?
• What must be described and justified regarding the investigational product?
• Essential Documents for the Conduct of a Clinical Trial are intended to permit evaluation of which aspects?
• What type of review does the IRB/IEC perform for trials?
• What statement best describes the purpose of direct access to source data and documents in GCP inspections?
• What is a primary purpose of Phase IV studies?
• Financing and insurance provisions should be described where if not addressed in a separate agreement?
• Which description best captures the essential focus when selecting a dose range in development planning?
• Which item is not included in the Introduction content?
• Which scenario best illustrates the scope of stopping rules within a trial protocol?
• Which document records that amendments and/or revisions have been subject to IRB/IEC review and were given approval/favorable opinion, and identifies the version number and date of the documents?
• Which document identifies subjects who entered pre-trial screening?
• Which statement best describes the close-out documentation requirements?
• If the trial is blinded, what must the investigator do in the event of any premature unblinding?
• In a crossover design, what is a key benefit for treatment comparisons?
• Which trial type has a rationale and design that rests on earlier work, and should have clear and precise objectives, though those objectives may not lead to simple tests?
• Which aspect most directly ensures the scientific integrity and credibility of a clinical trial's data?
• What is the primary purpose of expedited SUSAR reporting to regulatory authorities?
• If a sponsor transfers trial-related duties to a CRO, who retains ultimate responsibility for the quality and integrity of the trial data?
• Which component provides the procedures for eliciting reports of and for recording and reporting adverse events and intercurrent illnesses?
• Which records document that consent is obtained in accordance with GCP and protocol and dated prior to participation of each subject in trial, and also document direct access permission?
• Who should be responsible for all trial-related medical decisions?
• Which bodies may perform inspections of trial data and sites as part of QA activities?
• The IRB/IEC should retain all relevant records for a period of at least how long after completion?
• Expedited safety reports should comply with regulatory requirements and which ICH guideline?
• If a health issue is unrelated to the trial drug, how is it usually categorized?
• What is required before initiating a trial regarding Investigator's Brochure?
• Which design evaluates two or more treatments simultaneously by varying combinations of treatments?
• In the Background Information section, which item provides details about the investigational product?
• Who is responsible for selecting investigators/institutions?
• The sponsor's audit plan and procedures should be guided by which factors?
• Which records changes, additions, or corrections made to the Case Report Form after initial data were recorded?
• In Phase I, which objective is described as Estimation of initial safety and tolerability?
• What should be done with trial-related essential documents after the trial when there are still potential marketing applications?
• Which term is a description of a study described as a trial conducted in humans that is produced by integrating clinical and statistical descriptions in a single report?
• Sample size adjustment is used to account for what during a trial?
• For a non-therapeutic trial conducted with consent of the subject's legally acceptable representative, what must the IRB/IEC determine?
• Which document is used to determine the expectedness of an ADR?
• Which statement correctly describes the relationship between Adverse Drug Reaction and Adverse Event?
• Which design is used to facilitate interim analyses in clinical trials?
• Which term means prevention of disclosure, to other than authorized individuals, of a sponsor's proprietary information or of a subject's identity?
• When a subject withdraws from the trial, which data should be collected?
• Which document demonstrates that regulatory authorities have authorized/approved/notified the protocol prior to initiation of regulatory requirements?
• What is the role of randomization in a clinical trial?
• Which statement best describes the documentation of trial finances?
• What action should be taken with safety updates and periodic reports?
• Which item specifies the timing of any planned interim analysis?
• Which statement about Categorized Variables is correct?
• Which document includes original records related to the trial, to medical treatment, and history of the subject and substantiates the trial data?
• Which term is the formal written summary of the audit findings?
• After completion or termination, which set of documents should be retained?
• Which statement best describes data quality requirements for CRFs and required reports?
• If the IRB/IEC terminates or suspends its approval, what should the investigator do?
• What is the primary purpose of a sponsor's audit?
• What documentation should the sponsor obtain regarding IRB/IEC re-approvals or reevaluations?
• Which statement best describes a requirement of informed consent?
• If changes significantly affect the conduct of the trial or increase risk to subjects, how should the investigator report?
• Under what conditions may expedited review be provided for minor changes in ongoing trials?
• Which document lists all subjects enrolled and is kept confidential for potential follow-up?
• What must be included about the reporting source in expedited ADR reports?
• According to the material, the Investigator's Brochure serves to document which of the following?
• What is the purpose of reviewing the amount and method of payment to subjects?
• Which action should the investigator take if a trial is prematurely terminated or suspended?
• During participation, what must be provided to the subject when updates to consent are made?
• What is the sponsor's responsibility regarding site access for monitoring, auditing, and inspection?
• In emergency situations where prior consent is not possible, which statement is correct?
• Which term refers to an independent data-monitoring committee that may be established by the sponsor to assess at intervals the progress of a clinical trial, the safety data, and the critical efficacy endpoints, and to recommend to the sponsor whether to continue, modify, or stop a trial?
• Which statement best describes the investigator's obligation to communicate with the IRB/IEC?
• What is the role of the investigator in IRB/IEC deliberations?
• What is the role of an Independent Data-Monitoring Committee (IDMC)?
• Which document records that the investigator is informed in a timely manner of relevant information as it becomes available?
• Interim or annual reports to regulatory authorities are typically provided by which party?
• 4.5.2 states about deviations without agreement
• Which statement should be included in the statistical plan to describe interim analysis timing?
• Notification by sponsor and/or investigator to regulatory authorities and IRB/IECs of unexpected serious adverse drug reactions and other safety information is intended for which recipients?
• Under monitoring guidance, which statement correctly describes the 5.18.1 purpose?
• What does the Introduction convey about the product's identity and research rationale?
• Which item describes the known and potential risks and benefits to human subjects?
• Which data are considered source data in a GCP trial and should be recorded directly on the Case Report Form (CRF)?
• Early nonclinical safety studies should provide information to support which of the following, EXCEPT?
• The primary aim of protecting clinical trial subjects is to ensure what?
• During the trial, which entity monitors safety data continuously?
• Interim analyses may lead to early stopping when which conditions are met?
• Which topic describes the evaluation of safety and tolerability?
• Which principle guides respect for participants and an appropriate risk-benefit assessment in trials?
• Who is the person responsible for the conduct of the clinical trial at a trial site?
• How should the language of the consent information be written?
• Which design typically involves conducting trials across multiple research sites?
• Which statement best describes the design of a trial in terms of scientific quality?
• What must investigators maintain to demonstrate that subjects were provided the doses specified by the protocol and to reconcile all investigational product(s) received from the sponsor?
• Which statement is true about confidentiality and ongoing information for trial subjects?
• Which actions should be reported promptly to the IRB/IEC?
• Which statement is true about trial-related injury is required in the consent?
• What form must agreements between the sponsor and investigator or institution take?
• Which topic is addressed by the section that covers data integrity and computer software validity?
• Which term is a written, dated, and signed agreement between two or more involved parties that sets out any arrangements on delegation and distribution of tasks and obligations and, if appropriate, on financial matters?
• In a non-therapeutic trial, who normally must give consent and sign the written informed consent, unless an exception is justified?
• What is the retention requirement for essential trial documents after a study ends in an ICH region?
• Which statement expresses the requirement that participant safety and well-being take precedence over scientific or societal interests?
• Who is responsible for the accuracy of the clinical database summary?
• Which statement about payments to trial subjects is correct?
• Which body may be established by the sponsor to assess progress, safety data, and critical efficacy variables and to recommend continuation, modification, or termination?
• The protocol should include a description of the trial's type or design and what else?
• Which activity describes the IRB/IEC's scheduling and notification responsibilities?
• Which of the following best reflects Phase IV objectives related to patient populations?
• Which statement best describes data capture and processing responsibilities in GCP?
• Which document confirms that investigational products have been used according to the protocol?
• Which document demonstrates compliance with labeling regulations and the appropriateness of instructions provided to subjects?
• Which statement correctly describes sponsor auditing procedures?
• Which two roles are typically responsible for safety data collection and reporting in a trial?
• Who may vote or provide their opinion in IRB/IEC deliberations and discussions?
• If data are transformed during processing, what must be possible?
• Which statement is included to confirm compliance with protocol and regulatory requirements?
• Which entity should retain sponsor-specific essential documents related to the trial?
• Under which circumstances may protocol deviations or changes be initiated without prior IRB/IEC approval?
• Group sequential designs are used to facilitate the conduct of interim analyses.
• Which term refers to the judgement and/or advice provided by an Independent Ethics Committee (IEC)?
• What is the stated general expectation about on-site monitoring in trial monitoring guidance?
• What information should be provided for the physician or dentist responsible for site medical decisions when this person is not the investigator?
• Which term describes an investigator assigned the responsibility for the coordination of investigators at different centers participating in a multicenter trial?
• What role do data monitoring committees (DMC/DSMB) play in relation to the clinical database?
• Which term is the affirmative decision of the IRB that the trial may be conducted at the site within constraints?
• Which statement correctly reflects confidentiality of records in publications?
• What does the term 'Expectedness' refer to in the context of an ADR?
• Which term describes an individual responsible for the conduct of the clinical trial at a site?
• When should the investigator inform the subject about the need for medical care for intercurrent illness(es)?
• Which combination best describes the data transfer media used in data capture and processing?
• Which document specifies the master randomization list?
• What type of trial is designed to show that the investigational product is equivalent to, or not worse than, a reference treatment?
• What is the primary rationale for using multiple analysis sets?
• When may regulatory authorities access audit reports if not routinely requested?
• Prior to the trial, what must be obtained regarding the consent forms?
• Why should the Investigator's Brochure be updated?
• Which statement best describes a monitor's responsibility regarding informed consent?
• Which event would not typically be classified as a Serious Adverse Event?
• If IRB/IEC requires changes to the protocol or consent, what should the sponsor obtain?
• IRB/IEC procedures should be...
• Adverse events and/or laboratory abnormalities identified as critical to safety evaluations should be reported to the sponsor according to what?
• Regulatory reporting of unexpected serious adverse drug reactions: to whom should these be reported?
• If the Investigator's Brochure is updated during the trial, what should be done?
• Which entity is authorized under applicable law to consent on behalf of a prospective subject to participate in the trial?
• What should be adequate to support the proposed clinical trial regarding the investigational product?
• What is required when data on the CRF is derived from source documents?
• What is the recommended timing for reporting SAEs to the sponsor per GCP?
• In the context of Investigational Medicinal Products, which aspect should be well characterized in formulations used in clinical trials?
• Which document records shipment dates, batch numbers, and the method of shipment for investigational products and trial-related materials, enabling tracking and accountability?
• If new information becomes available that may affect a subject's willingness to continue participation, who should be informed?
• The physical and mental integrity of the subjects participating in a clinical trial is described as what?
• The sponsor should utilize qualified individuals throughout all stages of the trial for which purpose?
• The investigator should be aware of and comply with which requirements?
• What edition-related information is suggested to be provided?
• What term describes a clinical trial conducted according to a single protocol but at more than one site?
• Which information is included when discussing storage and handling?
• As part of the investigator's written application to the IRB/IEC, what must be provided?
• What term describes biomedical studies not performed on human subjects?
• What must be specified in the protocol regarding access to source data and documents?
• Which document records treatment allocation and any decoding events and is maintained to support blinding integrity?
• Which document confirms that all activities required for trial close-out are completed and copies of essential documents are filed?
• Who should retain sponsor-specific essential documents pertaining to the trial?
• What information must be described about investigational products?
• To preserve confidentiality, which identification method should be used in SAE reporting?
• How is subject safety addressed in a GCP trial?
• What should the Summary highlight according to the guidelines?
• During participation, what must be provided to the subject regarding consent updates?
• Which action relates to the investigational product and is a monitor's responsibility?
• Which document is used to document that an audit was performed, if available?
• Which document confirms that the site is suitable for the trial?
• What is the role of an independent data-monitoring committee (IDMC) in a clinical trial?
• What does the IRB/IEC conduct with regard to trials?
• Which type of trial is primarily intended to provide firm evidence of efficacy or safety?
• Which term refers to an independent body responsible for protecting rights, safety, and well-being of human subjects by reviewing, approving, and providing continuing review of trial protocols and informed consent documents?
• Who is responsible for retaining trial-related essential documents until the sponsor informs they are no longer needed?
• Which item summarizes findings from nonclinical studies and clinical trials relevant to the trial?
• What role do designated medical personnel play in the trial?
• In the Phase IV framework, which category specifically covers Studies of Drug Metabolites?
• Who should permit monitoring and auditing by the sponsor, and inspections by regulatory authorities?
• What is the compilation of clinical and nonclinical data on the investigational products relevant to the study called?
• Which statement best describes sponsor obligation in investigator selection?
• What statement best describes the relationship between exploratory and confirmatory trials?
• Which elements are included in the subject withdrawal criteria and procedure?
• What is the purpose of the sponsor notifying investigators of safety information?
• What is the purpose of Information Given to Trial Subject -- Informed Consent Form?
• Which items must the IRB/IEC promptly notify the investigator in writing?
• Which statement describes investigator obligations under 5.6.2 a-d?
• Which document records revisions to trial documents that take effect during the trial?
• In trials where enrollment can occur only with the consent of the subject's legally acceptable representative, if the subject is capable, what should occur regarding consent?
• Which element describes the methods and timing for assessing, recording, and analyzing efficacy parameters?
• In Phase I, pharmacokinetic studies may be conducted in which subjects?
• Which topic covers handling data gaps and unusual values in data?
• Which term describes permission to examine records and reports that are important to evaluation of a clinical trial?
• If significant formulation changes are made during clinical development, what must be available prior to using the new formulation in clinical trials?
• Which statement about non-therapeutic trials with LAR consent is NOT correct?
• Which document records the location and identification of retained body fluids/tissue samples if assays need to be repeated?
• Who informs the investigator when essential trial documents no longer need to be retained?
• If a deviation is implemented to eliminate an immediate hazard, what must be done?
• The sponsor should update the Investigator's Brochure in which scenario?
• What expenses information must be included in the consent?
• Which action is explicitly described as a sponsor responsibility related to stability and retention of the investigational product?
• Which topics are encompassed by the Estimation, Confidence Intervals and Hypothesis Testing section?
• The sponsor should submit to regulatory authorities all safety updates and periodic reports as required by which of the following?
• What information describes the expected duration of subject participation and the sequence of all trial periods?
• The role of attending the informed consent process if the subject or legal representative cannot read is associated with which role?
• Which term refers to the official review of documents, facilities, and records by a regulatory authority?
• Interim analyses may lead to early stopping if which conditions are met?
• Which data are typically included under efficacy data in a clinical trial report?
• Which bodies have the power to regulate clinical trials?
• When a death is reported in a clinical trial, what should the investigator provide to the sponsor and the IRB/IEC?
• Which statement about the Subject Screening Log is true?
• Global assessment variables are typically implemented as what kind of scale?
• Who is primarily responsible for supplying the investigational product to investigator sites?
• What term describes the planned and systematic actions to ensure trial activities comply with GCP and regulatory requirements?
• What documentation verifies the qualifications and eligibility of new investigators and/or sub-investigators to conduct the trial?
• Which term denotes the protection of a sponsor's proprietary information and participant identities from unauthorized disclosure?
• In describing the investigational product's physical, chemical, and pharmaceutical properties, which item must be included?
• Which option best describes the criterion that ensures staff are qualified for their tasks?
• Deviations from or changes to the protocol should not be initiated without prior written IRB/IEC approval except in which circumstances?
• Why must the protocol describe dosing schedules and follow-up periods for each treatment group?
• What topics should be included in the Effects in Humans: Introduction with respect to pharmacokinetics data?
• When must pharmacokinetic (PK) impact studies be available?
• What document records site visits by, and findings of, the monitor?
• Essential documents retention extension: It may be longer if required by what?
• Which item defines the safety endpoints to be monitored and how they are measured?
• What must be included in the written information provided to subjects regarding payment?
• What payment information must be included in the consent?
• Which party is responsible for the ongoing safety evaluation of the investigational product?
• The sponsor should utilize qualified individuals throughout all stages to do what?
• What must be provided to show the investigator's qualifications?
• Which action documents that the investigator or authorized staff confirms the observations recorded in the Case Report Form (CRF)?
• Which document records the final accounting of investigational products at the site?
• What is documented by Advertisement for Subject Recruitment?
• What must QA/QC ensure about data?
• How should the sponsor inform investigators about the need for record attention?
• Which design assigns a sequence of two or more treatments to the same participant, allowing them to serve as their own control?
• The Therapeutic Use category is associated with which of the following?
• What should be maintained by the IRB/IEC as part of its records?
• Should records identifying the subject be kept confidential and identity remain confidential when results are published?
• The brochure's purpose supports investigators in assessing risk-benefit for which aspect?
• Which element details the type and duration of the follow-up of subjects after adverse events?
• What should be done regarding patient compliance in a trial?
• How long should sponsor-specific essential documents be retained?